Form 4: Rocket Pharmaceuticals Officer Jonathan Schwartz Reports Stock Transactions

Jonathan Schwartz, Chief Medical & Gene Therapy Officer at Rocket Pharmaceuticals, reports the acquisition and disposal of common stock and stock options.

Summary

• On February 11, 2025, Jonathan Schwartz, Chief Medical & Gene Therapy Officer at Rocket Pharmaceuticals, reported transactions involving the company's stock.
• Schwartz acquired 80,318 shares of common stock.
• Schwartz disposed of 252,731 shares of common stock.
• Following these transactions, Schwartz beneficially owns 252,731 shares of common stock.
• Schwartz also acquired options to purchase 119,682 shares of common stock at an exercise price of $9.88.
• These options vest in equal installments beginning February 11, 2026, over the following two years, contingent upon continued employment.
• Following the transaction, Schwartz beneficially owns 119,682 derivative securities.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company officer. It doesn't inherently convey positive or negative sentiment.

Future Outlook

The vesting of the RSUs and stock options is contingent upon the reporting person's continued employment with the issuer.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the trading activities of company officers.

Stakeholder Impact

• The transactions may be of interest to shareholders as they provide insight into the actions of company leadership.

Key Dates